WO2003101434A3 - Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor - Google Patents

Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor Download PDF

Info

Publication number
WO2003101434A3
WO2003101434A3 PCT/IN2003/000205 IN0300205W WO03101434A3 WO 2003101434 A3 WO2003101434 A3 WO 2003101434A3 IN 0300205 W IN0300205 W IN 0300205W WO 03101434 A3 WO03101434 A3 WO 03101434A3
Authority
WO
WIPO (PCT)
Prior art keywords
intranasal
antihistamine
nasal mucosa
pharmaceutical compositions
loratadine
Prior art date
Application number
PCT/IN2003/000205
Other languages
French (fr)
Other versions
WO2003101434A2 (en
Inventor
Sampad Bhattacharya
Kiran Lagu
Sangeeta Chhabada
Original Assignee
Sampad Bhattacharya
Kiran Lagu
Sangeeta Chhabada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sampad Bhattacharya, Kiran Lagu, Sangeeta Chhabada filed Critical Sampad Bhattacharya
Priority to AU2003264859A priority Critical patent/AU2003264859A1/en
Publication of WO2003101434A2 publication Critical patent/WO2003101434A2/en
Publication of WO2003101434A3 publication Critical patent/WO2003101434A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition in the intranasal delivery to the nasal mucosa for prevention and treatment of symptoms of allergic rhiities and problems like nasal polyps comprising of Loratadine or Desloratadine which are potent antihistamine and solubilised at pharmaceutically acceptable pH of 4 to 8 which does not cause any irritation in the nose and permits the application of potent antihistamine at the site of action the nasal mucosa in lesser doses and without any side effect with immediate onset of action. Montelukast Sodium in combination with Loratadine would be very effective and gives some effect as intranasal steroids that without any side effects. Addition of pharmaceutical acceptable delivery vehicle help in forming intranasal application dosage units for applying the composition at nasal mucosa.
PCT/IN2003/000205 2001-12-21 2003-05-30 Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor WO2003101434A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003264859A AU2003264859A1 (en) 2001-12-21 2003-05-30 Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1202MU2001 2001-12-21
IN1202/MUM/2001 2002-05-30
IN503/MUM/2002 2002-06-06
IN503MU2002 2002-06-06

Publications (2)

Publication Number Publication Date
WO2003101434A2 WO2003101434A2 (en) 2003-12-11
WO2003101434A3 true WO2003101434A3 (en) 2004-03-25

Family

ID=29713472

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2003/000205 WO2003101434A2 (en) 2001-12-21 2003-05-30 Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor

Country Status (2)

Country Link
AU (1) AU2003264859A1 (en)
WO (1) WO2003101434A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US9149472B2 (en) 2004-08-31 2015-10-06 Jack William Schultz Controlled release compositions for treatment of cognitive, emotional and mental ailments and disorders
WO2007096733A2 (en) * 2006-02-22 2007-08-30 Orchid Chemicals & Pharmaceuticals Limited Desloratadine-containing formulation stabilized with cyclodextrin
EP2023957A2 (en) * 2006-06-07 2009-02-18 Morton Grove Pharmaceuticals, Inc. Oral liquid loratadine formulations and methods
TR200806298A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Pharmaceutical formulation
GB2465746B (en) 2008-11-21 2011-02-16 Fortune Apex Dev Ltd Pharmaceutical composition for topical application
WO2010107404A1 (en) * 2009-03-16 2010-09-23 Mahmut Bilgic Stable pharmaceutical combinations
TR201009398A2 (en) 2010-11-11 2012-05-21 Bi̇lgi̇ç Mahmut Tablet formulations with improved physical properties
PL2736491T3 (en) * 2011-01-04 2017-09-29 Bausch & Lomb Incorporated Bepotastine compositions
WO2013077829A1 (en) * 2011-11-21 2013-05-30 Mahmut Bilgic Water-soluble pharmaceutical granules
ES2745041T3 (en) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Use of levocetirizine and montelukast in the treatment of autoimmune disorders
JP6313414B2 (en) 2013-03-13 2018-04-18 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド Use of levocetirizine and montelukast in the treatment of traumatic injury
CA2928899C (en) * 2013-11-04 2021-02-16 Jack William SCHULTZ Treatment of cognitive, emotional and mental ailments and disorders
KR101555908B1 (en) * 2013-12-19 2015-09-25 한미약품 주식회사 Liquid formulation comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing the same
KR102391494B1 (en) * 2014-05-07 2022-04-28 한미약품 주식회사 Liquid formulation with enhanced stability comprising montelukast or pharmaceutically acceptable salt thereof and method for preparing same
EP3193875B1 (en) 2014-09-15 2022-02-16 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
WO2016140633A1 (en) * 2015-03-05 2016-09-09 BERAN Mehmet BERAT Formulations comprising montelukast
GB2577248A (en) * 2018-09-13 2020-03-25 Syri Ltd A pharmaceutical liquid composition of leukotriene receptor antagonist

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034611A1 (en) * 1997-02-11 1998-08-13 Sepracor, Inc. Methods and compositions for treating allergic asthma and other disorders using descarboethoxyloratadine
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
WO2001026658A2 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine
WO2001060407A2 (en) * 2000-02-17 2001-08-23 Viatris Gmbh & Co. Kg Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
US20020052388A1 (en) * 2000-10-30 2002-05-02 Schering Corporation Treatment method
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998034611A1 (en) * 1997-02-11 1998-08-13 Sepracor, Inc. Methods and compositions for treating allergic asthma and other disorders using descarboethoxyloratadine
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
WO2001026658A2 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine
WO2001060407A2 (en) * 2000-02-17 2001-08-23 Viatris Gmbh & Co. Kg Novel combination of non-sedative anti-histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjunctivitis
US20020052388A1 (en) * 2000-10-30 2002-05-02 Schering Corporation Treatment method

Also Published As

Publication number Publication date
WO2003101434A2 (en) 2003-12-11
AU2003264859A8 (en) 2003-12-19
AU2003264859A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
WO2003101434A3 (en) Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
RU2607892C2 (en) Composition based on xylitol, preventing separation of slime and related methods and compositions
ATE300282T1 (en) ORAL LIQUID MUCOADHESIVE COMPOSITIONS
ATE227978T1 (en) ORAL LIQUID MUCOADHESIVE COMPOSITIONS
JP6762931B2 (en) Improvement of nasal composition and usage of the nasal composition
BR9807673A (en) Processes to treat allergic asthma and dermatitis in a human and pharmaceutical composition.
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
NO20060328L (en) Combination of mGluR2 antagonist and ACHE inhibitor for the treatment of acute and / or chronic neurological disorders
WO2005058233A3 (en) Methods for treatment of acute pancreatitis
WO2007134241A3 (en) Nasal delivery of therapeutic agents using tight junction agonists
WO2005074983A3 (en) Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
JP5584713B2 (en) Nasal drops based on sodium azulenesulfonate
WO2004056320A3 (en) Compositions of non-steroidal anti-inflammatory drugs decongestants and anti-histamines
WO2006134492A3 (en) Acarbose methods and formulations for treating chronic constipation
DE602007014067D1 (en) Compositions and methods for treatment, control, reduction, improvement or the like PREVENTION OF ALLERGIES
WO2005039483A3 (en) Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity
WO2002017894A3 (en) Pharmaceutical formulation of salmeterol and fluticasone propionate
DE69903651T2 (en) ORAL LIQUID MUCOADHESIVE COMPOSITIONS
WO2000021512A3 (en) Composition and method for treating allergic diseases
IT202100021659A1 (en) Topical composition and its use for the nasal treatment of rhinitis
BR0003648A (en) Compositions and methods for treating allergic and inflammatory conditions with cough
ECSP993168A (en) COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES
DE60012586D1 (en) ANTI-MIGRAINE COMBINATION CONTAINING EXTRACTS FROM SAPINDUS AND EMBLICA
ECSP993167A (en) COMPOSITION AND METHOD FOR TREATING ALLERGIC DISEASES
BR0205625A (en) Nasal Formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP